Selected Grants
A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2025 - 2030A single-arm, open-label, Phase 2 study evaluating subcutaneous administration of isatuximab, administered by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and/or refractory
Clinical TrialPrincipal Investigator · Awarded by Sanofi US Services, Inc. · 2025 - 2030Phase 1b Dose Expansion Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis
Clinical TrialPrincipal Investigator · Awarded by Nexcella, Inc. · 2025 - 2030A Collaborative Community Effort using belantamab mafodotin in Relapsed/Refractory Myeloma
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2023 - 2030LCCC 1944
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2022 - 2027A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Clinical TrialPrincipal Investigator · Awarded by Kangpu Biopharmaceuticals, Ltd. · 2022 - 2027Prothena:A Phase 3, Randomized, Multicenter, Double-Blind,Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosi
Clinical TrialPrincipal Investigator · Awarded by Prothena Biosciences Limited · 2022 - 2027Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 302 py in Treatment Naive Patients with Stage IIIa or IIIb AL Cardiac
Clinical TrialPrincipal Investigator · Awarded by Caelum BioSciences, Inc · 2021 - 2026LARC multicenter retrospective Center-Based Chart Review
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2022 - 2025Glenmark Bite
Clinical TrialPrincipal Investigator · Awarded by Ichnos Science, S.A. · 2020 - 2025Caleium Pharm:Ph3 CAEL-101-301 AL Amyloidosis
Clinical TrialPrincipal Investigator · Awarded by Caelum BioSciences, Inc · 2021 - 2025A Pase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (anti-PDL1) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2019 - 2024External Relationships
- Sanofi Genzyme
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.